Activation of HCV-specific T cells
AssigneeChiron Corporation
InventorsXavier Paliard, Michael Houghton, Mark Selby
Life of this patent
Estimating the term…
Abstract
The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
Claims44
A fusion protein consisting essentially of an NS3, an NS4, and an NS5a polypeptide of a hepatitis C virus (HCV).
A fusion protein consisting essentially of an NS3, an NS4, an NS5a, and NS5b polypeptide of an HCV.
A composition consisting essentially of:
- (a) an isolated and purified NS3 polypeptide of a hepatitis C virus (HCV);
- (b) an isolated and purified NS4 polypeptide of a HCV;
- (c) an isolated and purified NS5a polypeptide of a HCV;
- and
- (d) a pharmaceutically acceptable excipient and optionally an adjuvant.
A composition consisting essentially of:
- (a) an isolated and purified NS3 polypeptide of a hepatitis C virus (HCV);
- (b) an isolated and purified NS4 polypeptide of a HCV;
- (c) an isolated and purified NS5a polypeptide of a HCV;
- (d) an isolated and purified NS5b polypeptide of a HCV;
- and
- (e) a pharmaceutically acceptable excipient and optionally an adjuvant.
A composition consisting essentially of:
- (a) an isolated and purified polynucleotide encoding an NS3 polypeptide of a hepatitis C virus (HCV);
- (b) an isolated and purified polynucleotide encoding an NS4 polypeptide of a HCV;
- (c) an isolated and purified polynucleotide encoding an NS5a polypeptide of a HCV;
- and
- (d) a pharmaceutically acceptable excipient and optionally an adjuvant.
A composition consisting essentially of:
- (a) an isolated and purified polynucleotide encoding an NS3 polypeptide of a hepatitis C virus (HCV);
- (b) an isolated and purified polynucleotide encoding an NS4 polypeptide of a HCV;
- (c) an isolated and purified polynucleotide encoding an NS5a polypeptide of a HCV;
- (d) an isolated and purified polynucleotide encoding an NS5b polypeptide of a HCV;
- and
- (e) a pharmaceutically acceptable excipient and optionally an adjuvant.
Dependencies are inferred from the claim text.